Tang L, Duan R, Zhong YJ, Firestone RA, Hong YP, Li JG, Xin YC, Wu HL, Li Y*. Synthesis, identification and in vivo studies of tumor-targeting agent peptide doxorubicin (PDOX) to treat peritoneal carcinomatosis of gastric cancer with similar efficacy but reduced toxicity .Mol Cancer. 2014;13:44.
Chen C, Yuan JP, Wei W, Tu Y, Yao F, Yang XQ, Sun JZ, Sun SR, Li Y*. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications. Int J Nanomed. 2014;9:1039-1048.
Hu WQ, Fang M, Zhao HL, Yan SG, Yuan JP, Peng CW, Yang GF, Li Y*, Li JD*. Tumor invasion unit in gastric cancer revealed by QDs-based in situ molecular imaging and multispectral analysis. Biomaterials.2014;35(13):4125-4132.
Wang Q, Zhong YJ, Yuan JP, Shao LH, Zhang J, Tang L, Liu SP, Hong YP, Firestone R, Li Y*. Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study. J Transl Med. 2013;11:192.
Fang M, Yuan JP, Peng CW, Pang DW, Li Y*. Quantum dots-based in situ molecular imaging of dynamic changes of collagen IV during cancer invasion. Biomaterials. 2013,34(34):8708-8717.
Peng CW, Wang LW, Fang M, Yang GF, Li Y*, Pang DW. Combined features based on MT1-MMP expression, CD11b + immunocytes density and LNR predict clinical outcomes of gastric cancer. J Transl Med. 2013,11:153.
Wang FB, Rong Y, Fang M, Yuan JP, Peng CW, Liu SP, Li Y*. Recognition and capture of metastatic hepatocellular carcinoma cells using aptamer conjugated quantum dots and magnetic particles. Biomaterials. 2013; 34: 3816-3827.
Shao LH, Liu SP, Hou JX, Zhang YH, Peng CW, Zhong YJ, Liu X, Liu XL, Hong YP, Firestone RA, Li Y*. Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis: an experimental study. Cancer. 2012.118(11):2986-2996.
Peng CW, Tian Q, Yang GF, Fang M, Zhang ZL, Peng J, Pang DW, Li Y*. Quantum-dots based simultaneous detection of multiple biomarkers of tumor stromal features to predict clinical outcomes in gastric cancer. Biomaterials. 2012;33(23):5742-5752.
Chen C, Peng J, Sun SR, Peng CW, Li Y*, Pang DW. Tapping the potential of quantum dots for personalized oncology: current status and future perspectives. Nanomedicine. 2012;7(3):411-428.
Li Y, Tang ZY, Hou JX. Hepatocellular carcinoma: insight from animal models. Nat Rev Gastroenterol Hepatol. 2012; 9(1):32-43.
Chen C, Sun SR, Gong YP, Qi CB, Peng CW, Yang XQ, Liu SP, Peng J, Zhu S, Hu MB, Pang DW, Li Y*. Quantum dots-based molecular classification of breast cancer by quantitative spectroanalysis of hormone receptors and HER2. Biomaterials.2011; 32(30):7592-7599.
Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Chen FL, Zhou YF, Xiong B, Yonemura Y, Li Y*. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011; 18(6):1575-1581.
Peng CW, Liu XL, Chen C, Liu X, Yang XQ, Pang DW, Zhu XB, Li Y*. Patterns of cancer invasion revealed by QDs-based quantitative multiplexed imaging of tumor microenvironment. Biomaterials. 2011; 32(11):2907-2917.
Chen C, Xia HS, Gong YP, Peng J, Peng CW, Hu MB, Zhu XB, Pang DW, Sun SR, Li Y*. The quantitative detection of total HER2 load by quantum dots and the identification of a new subtype of breast cancer with different 5-year prognosis. Biomaterials. 2010, 31(33):8818-8825.
Chen C, Peng J, Xia HS, Yang GF, Wu QS, Chen LD, Zeng LB, Zhang ZL, Pang DW, Li Y*. Quantum dots-based immunofluorescence technology for the quantitative determination of HER2 expression in breast cancer. Biomaterials. 2009; 30(15):2912-2918.
Yang XJ, Li Y*, Hassan AHA, Yang GL, Liu SY, Lu YL, Zhang JW, Yonemura Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases. Ann Surg Oncol. 2009; 16(2):345-351.
Chen LD, Liu J, Yu XF, He M, Pei XF, Tang ZY, Wang QQ, Pang DW, Li Y*. The biocompatibility of quantum dot probes used for the targeted imaging of hepatocellular carcinoma metastasis. Biomaterials. 2008; 29(31):4170-4176.
Li Y, Tang ZY, Tian B, Ye SL, Qin LX, Xue Q, Sun RX. Serum CYFRA 21-1 level reflects hepatocellular carcinoma metastasis: study in nude mice model and clinical patients. J Cancer Res Clin Oncol. 2006; 132(8):515-520.
Ding SJ, Li Y, Tan YX (coauthors), Jiang MR, Tian B, Liu YK, Shao XX, Ye SL, Wu JR, Zeng R, Wang HY, Tang ZY, Xia QC. From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics. 2004; 3(1):73-81.